X
New US legislation aims to expedite development of non-opioid pain drugs
https://pharmaphorum.com/news/new-us-legislation-aims-to-expedite-development-of-non-opioid-pain-drugs/
pain
FDA approves Teva’s higher-dose opioid dependence therapy
Cassipa is higher-dose version of Indivior’s Suboxone
Regeneron/Teva pain drug fasinumab on target in phase 3
Pfizer and Eli Lilly are competitors in NGF research
Pacira CEO hopes for further expansion to US nerve block label
CEO wants “broad nerve block label” for Exparel
FDA advisers reject new use for Pacira nerve block
Doubts over nerve blocker Exparel
SMi’s Pain Therapeutics Conference
Pain Therapeutics Conference
FDA approves Indivior’s long-lasting opioid withdrawal therapy
Monthly injection will help addicts manage withdrawal symptoms
FDA encourages cheap abuse-deterrent painkillers
Regulator waiting for non-opioid alternatives to reach the market
